Skip to search formSkip to main contentSkip to account menu

LEE011

Known as: LEE-011 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ribociclib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)
Natural killer/T-cell lymphoma (NKTCL) is an aggressive non-Hodgkin lymphoma that has been facing limited success with… 
2016
2016
Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.
568Background: Ribociclib (cyclin dependent kinase 4/6 inhibitor; LEE) acts synergistically with letrozole (LET) in preclinical… 
2015
2015
Abstract P5-19-24: Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis
Background: Activation of the PI3K/AKT/mTOR and cyclin D–CDK4/6–INK4–Rb pathways, including through alteration of PIK3CA and… 
2015
2015
Successful implementation of a novel trial model: The Signature program.
106 Background: Here we describe 8 ongoing single agent clinical protocols under Novartis’ “Signature” program involving… 
Highly Cited
2014
Highly Cited
2014
Molecular Pathways Molecular Pathways : CDK 4 Inhibitors for Cancer Therapy
Unrestrained growth is the hallmark of cancer, and disrupted cell-cycle regulation is, therefore, common. CDK4 is the key… 
2014
2014
Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).
533 Background: Postmenopausal women with advanced ER+ BC are usually treated with aromatase inhibitors (AIs) as first-line… 
2014
2014
Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
535 Background: Aromatase inhibitors (AIs) are the recommended first-line endocrine therapy for postmenopausal (PM) patients (pts… 
2014
2014
Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.
143 Background: Activation of the PI3K/AKT/mTOR and cyclin D-CDK4/6-INK4-Rb pathways has been implicated in endocrine therapy… 
2014
2014
1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA.
ABSTRACT Aim: Despite improvements in BRAF-mutant melanoma therapy, resistance is problematic. The cyclin D–CDK4/6–INK4A–Rb… 
2013
2013
Abstract S4-04: Overcoming resistance to PI3K inhibitors in PIK3CA mutant breast cancer using CDK4/6 inhibition: Results from a combinatorial drug screen
Various components of the phosphatidylinositol 3-kinase (PI3K) pathway are deregulated across a spectrum of human cancers… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)